Peptide benefits FAQ

LL-37 isn’t scheduled for FDA review until February 2027, so for now, its availability is strictly limited. It can be found in certain wellness clinics and medical spas around the country. One online purveyor that carries it in pharmaceutical grade is Bridgeside Telehealth. We’ve yet to come across another telehealth provider that has it. To get an LL-37 prescription in 2026, you must qualify for an exemption from the Federal Food, Drug, and Cosmetic Act, the set of laws that governs accessibility to restricted peptides. An exemption requires that the requested drug be “compounded for an identified individual patient based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient.” 18 In lay terms, that means a licensed clinician must consider the drug to be medically necessary for the patient, with the caveat that no other, more widely available treatment would be suitable. Future availability hinges on the outcome of the FDA’s review in 2027. If the Administration determines that LL-37 should be moved from Category 2 into Category 1, prospective patients will need only a standard prescription, as they would with mainstream peptides such as semaglutide. Again, we’ll be following developments closely and will update this guide as new information comes to light.

The most likely candidates for LL-37 are people recovering from invasive surgery — around 0.5–3.0% of all surgical patients, by one estimate. 15 Within that cohort are subsets that are at higher risk of infection, and therefore have a greater need for LL-37, than others. For example: 16 The elderly The immunocompromised Current smokers People with diabetes, overweight, or obesity People whose surgeries lasted longer than 2 hours Cancer is another factor that increases one’s risk of developing a postoperative infection, but it also appears to be a contraindication for LL-37 owing to its pro-tumorigenic action. So anyone with a personal or family history of cancer probably would be excluded as a candidate. The same might be said about people with chronic inflammatory health conditions. Even though LL-37 plays a regulatory role in the body’s inflammatory response, it may also exacerbate inflammatory disorders (e.g., psoriasis). 17

Given LL-37’s current restricted status and attendant rarity on the prescription market, we can’t rightly delineate a standard treatment protocol for it. But based on the existing research, we can deduce at least a few aspects of the LL-37 use experience.

LL-37 belongs to a family of antimicrobial peptides called cathelicidins — hence its full and proper name, cathelicidin LL-37 . Cathelicidins occur naturally in animal organisms, as innate components of the immune system. Around 30 cathelicidins have been identified in mammalian species, of which LL-37 is the only one that has yet been found in humans. 1 The “37” part of its name refers to the total number of amino acids in its sequence, and “LL” indicates the first two (leucine). In the human body, cathelicidin LL-37 has both a direct and an indirect antimicrobial function. In the presence of bacteria, viruses, fungi, or parasites, it can bind to and destroy the invading pathogen. Elsewise, it modulates the inflammatory response, directs immune cells to the site of infection, and differentiates T cells into different immune cell types, helping to give the body a better fighting chance against whatever’s ailing it. 2

With regard to safety, LL-37 has a few issues. As of 2026, LL-37 remains on the Category 2 list of bulk drug substances, a roster of substances that the United States Food & Drug Administration (FDA) has identified as posing significant safety risks . The FDA has presented a fourfold reasoning for LL-37’s placement in this category: 11 Immunogenicity: By some routes of administration, LL-37 may trigger an immune response in which the body regards it as a harmful substance, possibly owing to “complexities with regard to peptide-related impurities and API characterization.” Called immunogenicity , this immune response is similar to an allergic reaction and can be similarly life-threatening. “Detrimental effects on male reproduction”: Nonclinical studies suggest that LL-37 is capable of spermicidal activity. These studies have examined the peptide’s effects on both animal and human sperm. 12 Tumorigenesis: According to some research studies, LL-37 may spur tumor growth in the ovaries, lungs, breasts, prostate, pancreas, and skin. 13 Lack of safety studies: Per the FDA, there isn’t enough “safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans.” Recall, though, that a 2014 randomized, placebo-controlled trial reported “no safety concerns regarding local or systemic adverse events.” Though that would seem to contradict the FDA’s official statements about LL-37, it’s still just one study. As LL-37 will soon come under FDA review for potential recategorization, we may see an increase in human research on the peptide, revealing whether it’s safer or more dangerous than the existing literature suggests. We’ll be following such developments and updating this guide accordingly.

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles. At this writing, we’ve cumulatively spent over 1,000 hours researching therapeutic peptides. Not just the mainstream weight-loss ones, either, but also the obscure and the experimental, like LL-37. Each piece we’ve written is built upon the available scientific literature on the subject. When possible, we’ve also incorporated the ground-view perspectives of doctors and patients — people who know intimately how peptides work and whom they might best serve. Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

Just as efficacy studies on PE-22-28 are severely lacking, safety evaluations are practically nonexistent. The closest thing we have to research conclusions on the drug’s tolerability are more or less passing statements, and not about PE-22-28 specifically: “The absence of adverse effects differentiates spadin-analogs [ sic ] from other antidepressant drugs.” 8 “At the cardiovascular level, long-term treatment by spadin has no effect on systolic blood pressure and heart pulses.” 13 Though both assessments are broadly positive, neither one is exactly an endorsement of PE-22-28’s safety. Perhaps more notably, however, PE-22-28 is one of the few restricted peptides we’ve covered that the United States Food & Drug Administration (FDA) has not flagged as a bulk drug substance that may present significant safety risks. 14 Normally, when we discuss a non-GLP-1 peptide therapy, we find that the FDA has published good reasons for having denied the peptide’s approval (e.g., immunogenicity or other serious adverse effects), but that isn’t the case here. That is, the FDA hasn’t explicitly said that PE-22-28 may be unsafe. At the same time, the absence of a federal warning isn’t the same as evidence of a drug’s safety. The bare fact is that PE-22-28 doesn’t have enough research behind it to say much about its health risks or lack thereof. It’s simply invisible on the FDA’s radar until human trials enter the picture.

With what we know about PE-22-28, we’d say the most suitable candidate for the peptide is someone who: Lives with a mood disorder, such as depression Is willing to try an experimental therapy Also, because it’s commonly administered via intranasal spray, PE-22-28 is a viable option for those who’d rather not deal with needles. As for who isn’t suited for treatment, it’s likely the usual cohorts. Pregnant or breastfeeding women may be contraindicated, as may be anyone with a history of cancer , given how little is known about PE-22-28’s effects on fetal/child development and tumorigenesis. But even among the indicated population, PE-22-28 should be regarded with sober expectations. As of this writing, the peptide has yet to withstand the crucible of clinical trials, so it’s unclear whether its effects on rodents can be recreated in humans, or what its safety profile will ultimately look like. So, whether you’re a candidate or not, you’ll want to speak with your doctor about PE-22-28. If they feel that PE-22-28 can improve your symptoms better than a more common antidepressant, then you can go about obtaining a prescription.

With neither common use nor human studies behind it, PE-22-28 can hardly be said to have a standard treatment protocol. But there are several known treatment factors about PE-22-28, and we can lean on our relationships with clinicians to fill in the blanks.

PE-22-28 is an analog fragment of another peptide, spadin, that occurs naturally in the human body. Both spadin and PE-22-28 selectively antagonize a two-pore domain potassium (K2P) channel called TREK-1 . K2P channels are a kind of protein that regulates neurotransmitter release in the brain and the ability of neurons to respond to stimuli. 3 In these roles, they take part in numerous biological functions — hormone secretion, 4 pain processing, eye pressure regulation, 5 etc. — but when overexpressed, they can also contribute to several pathologies. TREK-1, in particular, is implicated in depression, which is associated with weakened neuronal excitability. 6 7 TREK-1’s influence on depression and related disorders is what PE-22-28 and spadin act on. By selectively antagonizing this K2P channel, PE-22-28 blocks an inhibitory mechanism that contributes to the mood problem. Where PE-22-28 diverges from spadin is in its stability and efficacy. Studies have shown, for example, that PE-22-28’s duration of action is more than three times longer than that of spadin, its antidepressant effects lasting nearly a whole day as opposed to just seven hours. 8

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles. At this point, we’ve put more than 1,000 hours of research and writing into peptides. Our work has taken us through several peptide therapies with neurocognitive and mood-stabilizing effects, giving us multiple points of reference on where PE-22-28 stands in this space. Our peptide-related work has also involved discussions with clinicians who prescribe peptides and people who use them, imbuing our guides with multifaceted perspectives that can better guide readers’ health decisions. Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

Getting your primary care provider to write a PE-22-28 prescription may be a tough go. With well-tested SSRIs at their disposal, they aren’t likely to consider an unproven, experimental peptide unless all reasonable alternatives have been exhausted. That means you’ll probably need a licensed provider at a peptide clinic to fill the script instead. To that end, you can either look locally or look online. For the online route, the ideal source for PE-22-28 would be a licensed telehealth outfit, which can adjust your therapy as needed, not just send you the product and wish you luck. The legal and regulatory status of therapeutic peptides is always in flux. If and whenever PE-22-28 becomes more widely available to health consumers, we’ll update this guide with the latest research and recommendations.

Switch to N-acetylcysteine (NAC) at 600–1200mg daily, which provides cysteine. The rate-limiting amino acid for glutathione synthesis. In a form that survives digestion. Standard oral glutathione degrades before absorption, so blood glutathione levels rarely increase more than 10–20% even with high-dose supplementation. NAC circumvents this by delivering the precursor that cells use to synthesize glutathione endogenously. Liposomal glutathione formulations show better absorption than standard capsules, but NAC remains the most cost-effective and well-studied approach for raising intracellular glutathione.

Measure both reduced GSH and oxidized GSSG separately using HPLC or spectrophotometric assays, then calculate the GSH:GSSG ratio. A more informative marker of redox status than total glutathione alone. A healthy cell maintains a GSH:GSSG ratio above 100:1 under basal conditions. Ratios below 10:1 indicate severe oxidative stress and impaired antioxidant capacity. Direct glutathione measurement requires immediate sample processing because GSH auto-oxidizes in lysates within minutes. Some protocols recommend adding metaphosphoric acid to precipitate proteins and stabilize thiols immediately after cell lysis.

Store samples at −80°C immediately after collection and add N-ethylmaleimide (NEM) at the time of homogenization to prevent post-collection oxidation of GSH to GSSG. Glutathione oxidizes rapidly in biological samples once removed from the reducing environment of the cell. A 37°C incubation can convert 50% of GSH to GSSG within 30 minutes. NEM alkylates free thiol groups, locking glutathione in its reduced form for accurate measurement. Most commercial glutathione assay kits include NEM in the sample buffer, but verifying its presence before processing prevents false low GSH readings.

Discard the vial immediately. Any temperature excursion above 8°C for more than 2–3 hours denatures the peptide structure irreversibly. The solution may still look clear and sterile, but potency is compromised. Thymalin's polypeptide chains are temperature-sensitive; once denatured, no amount of refrigeration restores bioactivity. This is the single most common preparation error that wastes expensive peptides.

Thymalin for men is compatible with exogenous testosterone. The mechanisms don't overlap enough to create redundancy. Thymalin modulates upstream LH signalling, while TRT replaces testosterone directly. Combining both may preserve some endogenous testicular function during TRT, though this hasn't been formally studied. Standard stacking protocol: continue TRT at prescribed dose; add thymalin 5mg every other day for 20 days once every 3–4 months.

Administer thymalin for the full 10-day protocol before assessing efficacy. Immune markers like CD4+ counts and thymulin levels don't shift measurably until 14–21 days post-cycle. If no subjective improvements (fewer infections, faster recovery from illness) appear by week 4, reassess dosing or consider stacking with Cerebrolysin to address neuroinflammation that may be masking immune gains.

Temporarily reduce the dose to 5mg every other day rather than daily. Joint pain and transient fatigue can occur during the first 3–5 days as immune reactivation triggers mild inflammatory responses. This resolves as T-cell populations stabilise. If symptoms persist beyond day 7, discontinue thymalin and assess for underlying autoimmune conditions that contraindicate immune-stimulating peptides.